Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Histopathology Retrieve available abstracts of 21 articles: HTML format

Single Articles

August 2025
1. NEIL AJ, Nkosi D, Yoon JY, Kolin DL, et al
   Molecular and immunohistochemical characterization of ERBB2 activating mutations in low-grade serous ovarian carcinoma.
   Histopathology. 2025;87:310-320.
   PubMed     Abstract available
   
   
   November 2024
2. ZHANG X, McCluggage WG, Howitt BE, Hirsch MS, et al
   SOX17 expression in mesonephric-like adenocarcinomas and mesonephric remnants/hyperplasia of the female genital tract: Expanding its utility as a Mullerian biomarker.
   Histopathology. 2024;85:820-825.
   PubMed     Abstract available
   
   
   
3. DEHGHANI A, Sharma AE, Siegmund SE, Carreon CK, et al
   STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours.
   Histopathology. 2024;85:769-782.
   PubMed     Abstract available
   
   
   
4. X ZHANG G, Yang B
   Retained PAX2 expression associated with DNA mismatch repair deficiency in endometrial endometrioid adenocarcinoma.
   Histopathology. 2024;85:794-803.
   PubMed     Abstract available
   
   
   October 2024
5. RICCI C, Ambrosi F, Grillini A, Grillini M, et al
   Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and 'somatic-type' adenocarcinoma.
   Histopathology. 2024;85:695-698.
   PubMed    
   
   
   
6. ALAFRAIDI M, Hoang L, Howitt BE, Longacre TA, et al
   The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile.
   Histopathology. 2024;85:660-670.
   PubMed     Abstract available
   
   
   
7. MCHENRY A, Devereaux K, Ryan E, Chow S, et al
   Molecular classification of metastatic and recurrent endometrial endometrioid carcinoma: prognostic relevance among low- and high-stage tumours.
   Histopathology. 2024;85:614-626.
   PubMed     Abstract available
   
   
   
8. WYVEKENS N, Mutter GL, Nucci MR, Kolin DL, et al
   Lesions sub-diagnostic of endometrioid intra-epithelial neoplasia/atypical hyperplasia: value of morphology and immunohistochemistry in predicting neoplastic outcome.
   Histopathology. 2024;85:579-589.
   PubMed     Abstract available
   
   
   June 2024
9. PARRA-HERRAN C, Dundr P, McCluggage WG
   Editorial: Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
   Histopathology. 2024;84:1092-1094.
   PubMed    
   
   
   
10. KOBEL M, Kang EY, Lee S, Terzic T, et al
    Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
    Histopathology. 2024;84:1095-1110.
    PubMed     Abstract available
    
    
    May 2024
11. ANGELICO G, Salvatorelli L, Tinnirello G, Santoro A, et al
    The first evidence of mismatch repair deficiency in mesonephric-like adenocarcinoma of the endometrium: clinicopathological and molecular features of a case emphasising a possible endometrioid carcinogenesis.
    Histopathology. 2024;84:1068-1070.
    PubMed    
    
    
    March 2024
12. KOMMOSS FKF
    Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour.
    Histopathology. 2024;84:712-714.
    PubMed     Abstract available
    
    
    
13. KOMMOSS FKF, Chong AS, Apellaniz-Ruiz M, Turashvili G, et al
    Teratoma-associated and so-called pure Wilms tumour of the ovary represent two separate tumour types with distinct molecular features.
    Histopathology. 2024;84:683-696.
    PubMed     Abstract available
    
    
    January 2024
14. MCCLUGGAGE WG
    Editorial on: Role of gene sequencing in classifying struma ovarii: BRAF P.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Histopathology. 2024;84:288-290.
    PubMed    
    
    
    
15. NEIL AJ, Li YY, Hakam A, Nucci MR, et al
    Pattern A endocervical adenocarcinomas with ovarian metastasis are indolent and molecularly distinct from destructively invasive adenocarcinomas.
    Histopathology. 2024;84:369-380.
    PubMed     Abstract available
    
    
    
16. NEYRAND S, Trecourt A, Lopez J, Just PA, et al
    Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii.
    Histopathology. 2024;84:291-300.
    PubMed     Abstract available
    
    
    September 2023
17. MACHUCA-AGUADO J, McCluggage WG
    'STIC-like' lesions in ovarian low-grade serous carcinoma: a diagnostic pitfall.
    Histopathology. 2023;83:489-492.
    PubMed    
    
    
    
18. RICCI C, Ambrosi F, Franceschini T, Giunchi F, et al
    FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type.
    Histopathology. 2023;83:465-476.
    PubMed     Abstract available
    
    
    July 2023
19. THORNE H, Devereux L, Li J, Alsop K, et al
    BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
    Histopathology. 2023;83:91-103.
    PubMed     Abstract available
    
    
    
20. BOGAERTS JMA, van Bommel MHD, Hermens RPMG, Steenbeek MP, et al
    Consensus based recommendations for the diagnosis of serous tubal intraepithelial carcinoma: an international Delphi study.
    Histopathology. 2023;83:67-79.
    PubMed     Abstract available
    
    
    June 2023
21. MIRKOVIC J, Olkhov-Mitsel E, Amemiya Y, Al-Hussaini M, et al
    Mesonephric-like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric-like carcinosarcomas.
    Histopathology. 2023;82:978-990.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.